drugset / Trial / NCT03758612
A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of TBI-223 in Healthy Adults
RandomizedParallel-groupTriple-blindTreatment
Summary
Partially-Blinded, Placebo-Controlled, Randomized, Single Ascending Dose (SAD) with a Food Effect Cohort to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBI-223 in Healthy Adults.
Timeline
- Start
- 2019-01-16
- Primary completion
- 2020-03-15
- Completion
- 2020-03-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | TBI-223 | Small molecule | 50 mg | Oral |
| Comparator | TBI-223 | Small molecule | 100 mg | Oral |
| Comparator | TBI-223 | Small molecule | 300 mg | Oral |
| Comparator | TBI-223 | Small molecule | 600 mg | Oral |
| Comparator | TBI-223 | Small molecule | 1200 mg | Oral |
| Comparator | TBI-223 | Small molecule | 1800 mg | Oral |
| Comparator | TBI-223 | Small molecule | 2000 mg | Oral |
| Comparator | TBI-223 | Small molecule | 2600 mg | Oral |